Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab Maintenance After Concurrent Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma
ChiCTR2600116088Phase 4Not yet recruiting
- Sponsor
- Meishan City People's Hospital
- Start
- Jan 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tislelizumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Meishan City People's Hospital. Primary endpoints: Objective Response Rate (ORR), Adverse Reaction Incidence Rate and 1 more. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
tislelizumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2600116088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600116088.